| Literature DB >> 32661702 |
Bianca Sieveritz1, Gordon W Arbuthnott2.
Abstract
Ventromedial thalamic axons innervate cortical layer I and make contacts onto the apical dendritic tuft of pyramidal neurons. Optical stimulation of ventromedial thalamic axon terminals in prefrontal cortical areas in mouse brain slices evokes responses in corticocortical, corticothalamic and layer I inhibitory interneurons. Using anterograde tracing techniques and immunohistochemistry in male Sprague-Dawley rats, we provide anatomical evidence that ventromedial thalamic axon terminals in prelimbic cortex make contacts onto pyramidal neurons and, in particular, onto corticostriatal neurons as well as layer I inhibitory interneurons. Using stereology, we made quantitative estimates of contacts in uppermost prelimbic layer I onto dendrites of pyramidal neurons, corticostriatal neurons and layer I inhibitory interneurons. Prefrontal cortex has long been associated with decision making. Specifically, corticostriatal neurons in rat prelimbic cortex play an important role in cost-benefit decision making. Although recent experiments have detailed the physiology of this area in thalamocortical circuits, the extent of the impact of ventromedial thalamic input on corticostriatal neurons or layer I inhibitory interneurons has not been explored. Our quantitative anatomical results provide evidence that most ventromedial thalamic input to pyramidal neurons is provided to corticostriatal neurons and that overall more contacts are made onto the population of excitatory than onto the population of inhibitory neurons.Entities:
Keywords: 5HT3aR; Corticostriatal neurons; Inhibitory interneurons; Prelimbic cortex; RGS14; Ventromedial thalamus
Mesh:
Substances:
Year: 2020 PMID: 32661702 PMCID: PMC7473973 DOI: 10.1007/s00429-020-02109-3
Source DB: PubMed Journal: Brain Struct Funct ISSN: 1863-2653 Impact factor: 3.270
Fig. 1The extent of prelimbic cortex was defined in accordance with borders presented in a rat brain atlas (Paxinos and Watson 2004). The boundaries of prelimbic cortex based on this definition are illustrated in this figure (PrL prelimbic cortex, M2 secondary motor cortex, MO medial orbital cortex, Cg1 cingulate cortex, area 1, IL infralimbic cortex, DP dorsal peduncular cortex)
Primary and secondary antibodies used in immunohistochemistry
| Primary antibody | Secondary antibody |
|---|---|
| Rabbit anti-choleratoxin subunit-B (abcam, #ab34992, RRID: AB_726859): 1:1000 dilution, 0.15–0.3% Triton X-100, 18-36 h incubation time | Alexa Fluor 594 goat anti-rabbit: 1:200 dilution, 2–3 h incubation time |
| Mouse anti-GAD67 (Millipore, #MAB5406, RRID: AB_2278725): 1:1000 dilution, 0.15–0.3% Triton X-100, 18-36 h incubation time | Alexa Fluor 488/594/633 goat anti-mouse: 1:200 dilution, 2–3 h incubation time |
| Guinea pig anti-VGluT1 (Millipore, #AB5905, RRID: AB_2301751): 1:500 dilution, 0.3% Triton X-100, 18 h incubation time | Alexa Fluor 594 goat anti-guinea pig: 1:200 dilution, 3 h incubation time |
| Rabbit anti-VGluT2 (Sigma Aldrich, #V2514, RRID: AB_477611): 1:1000 dilution, 0.3% Triton X-100, 18 h incubation time | Alexa Fluor 405 goat anti-rabbit: 1:200 dilution, 3 h incubation time |
| Rabbit anti-PSD95 (abcam, #ab76115, RRID: AB_1310620): 1:200 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 405 goat anti-rabbit: 1:200 dilution, 2 h incubation time |
| Mouse anti-PSD95 (Invitrogen, #MA1-046, RRID: AB_2092361): 1:1000 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 405 goat anti-mouse: 1:200 dilution, 2 h incubation time |
| Guinea pig anti-synaptophysin 1 (Synaptic systems, #101 004, RRID: AB_1210382): 1:500 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 594 goat anti-guinea pig: 1:200 dilution, 2 h incubation time |
| Rabbit anti-MAP2 (abcam, #ab32454, RRID: AB_776174): 1:500 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 488 goat anti-rabbit: 1:200 dilution, 2 h incubation time |
| Mouse anti-RGS14 (NeuroMabs, #73–170, RRID: AB_10698026): 1:500 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 488 goat anti-mouse: 1:200 dilution, 2 h incubation time |
| Rabbit anti-5HT3aR (Invitrogen, #PA1-41,033, RRID: AB_2248968): 1:500 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 488 goat anti-rabbit: 1:200 dilution, 2 h incubation time |
| Chicken anti-MAP2 (abcam, #ab5392, RRID: AB_2138153): 1:500 dilution, 0.15% Triton X-100, 36 h incubation time | Alexa Fluor 633 goat anti-chicken: 1:200 dilution, 2 h incubation time |
A summary of dilutions of primary and secondary antibodies in respective antibody solutions, the concentration of Triton X-100 in primary antibody solutions, and incubation times of sections
Used fluorochromes
| Fluorochrome | Excitation | Emission | Light source | Filter set | Emission range |
|---|---|---|---|---|---|
| DAPI | 358 nm | 461 nm | 405–30 laser diode | MBS 488/561/633 dichroic beam splitter; MBS − 405 dichroic beam splitter | Simultaneous use of Alexa Fluor 488: 410–495 nm. Otherwise: 410–579 nm |
| Alexa Fluor 405 | 401 nm | 421 nm | 405–30 laser diode | MBS 488/561/633 dichroic beam splitter; MBS − 405 dichroic beam splitter | 410–489 nm |
| Alexa Fluor 488 | 496 nm | 519 nm | Argon laser | MBS 488 dichroic beam splitter | Simultaneous use of Alexa Fluor 594: 489–588 nm. Otherwise: 493–630 nm |
| GFP | 395 nm | 509 nm | Argon laser | MBS 488 dichroic beam splitter | 489–588 nm |
| Tetramethyl-Rhodamine | 557 nm | 576 nm | DPSS 561–10 laser | MBS 458/561 dichroic beam splitter | 568–691 nm |
| Alexa Fluor 594 | 590 nm | 617 nm | DPSS 561–10 laser | MBS 458/561 dichroic beam splitter | Simultaneous use of Alexa Fluor 633: 587–633 nm. Otherwise: 585–735 nm |
| Alexa Fluor 633 | 633 nm | 647 nm | HeNe633 laser | MBS 488/561/633 dichroic beam splitter | 638–747 nm |
Overview of the excitation and emission peak of used fluorochromes, the light source and filter set used for excitation, and the emission range used
Fig. 2Stereology. The sampling area, defined a priori, consisting of the uppermost 40 µm of prelimbic cortex in each third section is shaded in grey. In each image stack, the sampling area was outlined in the optical fractionator workflow in Stereo Investigator (MBF Biosciences) and the workflow placed the optical dissector grid randomly across it. The fractionator was placed systematically along the optical dissector grid to select sampling sites and define the size of each sampling site
Fig. 3Expression of RGS14 and 5HT3aR at postsynaptic sites, and expression of RGS14 along dendrites of pyramidal neurons. a In prelimbic cortical layer I RGS14 (green) and b 5HT3aR (green) are expressed at postsynaptic sites marked with PSD95 (blue) rather than at presynaptic sites marked with SOP (magenta). Yellow arrowheads mark expression of RGS14 and 5HT3aR in postsynaptic sites. c Furthermore, in prelimbic cortical layers II/III RGS14 (green) is expressed along dendrites of pyramidal neurons marked with MAP2 (magenta). Yellow arrowheads mark expression of RGS14 along dendrites. Animal numbers do not correspond to animal numbers used in later figures
Fig. 4RGS14 expression in prelimbic cortex. a CS neurons that were retrogradely labeled with choleratoxin subunit B (ChTx, red) express RGS14 (green) and MAP2 (magenta) in prelimbic cortex, which is outlined by the yellow dashed line. b Injection site of choleratoxin subunit B (red) in dorsomedial striatum. c Injection site of choleratoxin subunit B (red) in ventral motor and adjacent thalamic nuclei. d CS neurons in prelimbic cortex that were retrogradely labeled with choleratoxin subunit B (ChTx; red) from dorsomedial striatum express RGS14 (green) and MAP2 (magenta), while e CT neurons do not express RGS14 (green) in the somata. Yellow arrowheads mark sparse expression of RGS14 along the outer membrane of the cell nuclei or in the somata that was observed in very few CT neurons in prelimbic cortex. Cell nuclei are counterstained with DAPI (blue)
Fig. 55HT3aR expression in prelimbic cortex. a Expression of 5HT3aR (green) and GAD67 (magenta) in prelimbic cortex that is outlined by the yellow dashed line. b In prelimbic layer I inhibitory interneurons that were labeled with GAD67 (GAD67-positive; magenta) express 5HT3aR (green), while those that do not express GAD67 (GAD67-negative; magenta) do not express 5HT3aR (green). Cell nuclei were counterstained with DAPI (blue)
Fig. 6VM axon terminals in prelimbic cortex express VGluT2 and to less extent VGluT1 but not GAD67. a Injection of the anterograde tracer AAV5-CAG-ArchT-GFP (green) into ventral motor thalamus, which was labeled with GAD67 (magenta), b labeled ventral motor thalamic axon terminals (green) in a prefrontal cortical section (left). Prefrontal cortex in this section is outlined by a yellow dashed line. Specifically, ventral motor thalamic axon terminals (green) spanned the full length from the dorsal end of prelimbic cortex that borders with anterior cingulate cortex (top enlarged image in the middle) to the ventral end of prelimbic cortex that borders with infralimbic cortex (bottom enlarged image in the middle). Varicosities along one axon that is located at the edge of anterior cingulate and prelimbic cortex are shown in a high magnification image (enlarged image on the right; yellow arrowheads mark varicosities). Cell nuclei in the section were counterstained with DAPI (blue). c In maximum intensity projections taken over an image stack with 10 single focal plane images that each spanned 0.58 µm ventral motor thalamic axon terminals (green) overlapped with VGluT2 (magenta) and to less extent VGluT1 (magenta) and GAD67 (magenta). VGluT2, VGluT1 and GAD67 were labeled in adjacent slices and, hence, are all shown in magenta. d However, in single focal plane images spanning 0.58 µm ventral motor thalamic axon terminals (green) were only found to express VGluT2 (magenta) and to less extent VGluT1 (magenta), but not GAD67 (magenta). Yellow arrowheads in c and d mark expression of VGluT2, VGluT1 and GAD67 and the yellow dashed lines mark midline
Fig. 9VM axon terminals in prelimbic cortex make contacts onto dendrites of pyramidal neurons, CS neurons and 5HT3aR-positive inhibitory interneurons in layer I. a Imaging data were obtained in three animals at 0.3, 0.7 and 1.1 mm ventral from the dorsal end of prelimbic cortex at sites marked with yellow arrowheads in Fig. 8. VM axon terminals in uppermost prelimbic cortical layer I (magenta) superimpose with MAP2 (green) that labels dendrites of cortical pyramidal neurons, b RGS14 (green) that labels synaptic sites along dendrites of CS neurons, and c 5HT3aR (green) that labels synaptic sites along the dendrites of 5HT3aR-positive inhibitory interneurons. Yellow arrowheads indicate superimpositions. Images illustrating superimpositions have been cropped from single focal plane images. Each single focal plane image spanned 0.29 μm. Animal numbers correspond to animal numbers in Fig. 7, which illustrates the spread of injections in all seven animals. d 3D-reconstructions of selected contacts between incoming VM axon terminals and each marker
Fig. 7Mini-ruby injections were mostly confined to VM. a The anterograde tracer mini-ruby (magenta) was injected into VM that was labeled with GAD67 (green) and counterstained with DAPI (blue) to visualize cell nuclei. b The spread of injections is illustrated for all seven animals. Injections were mostly confined to VM. Illustrations of VM and surrounding brain areas are replicated from Swanson (2004), an open-source rat brain atlas
Fig. 8Mini-ruby, MAP2, RGS14 and 5HT3aR expression in prelimbic cortex. a The anterograde tracer mini-ruby (magenta) labeled VM axon terminals in prelimbic cortex, which is outlined by a yellow dashed line. High magnification images on the right illustrate that mini-ruby is expressed in axons and varicosities along these axons. Axons and varicosities are marked by yellow arrowheads. b MAP2 (green), c RGS14 (green) and d 5HT3aR (green) are expressed throughout prelimbic cortex. The same section is presented in a, b with a only showing fluorescence from the mini-ruby (magenta), while b shows fluorescence from the mini-ruby (magenta), MAP2 (green) and DAPI (blue). In c and d adjacent sections are shown that also contain fluorescence from mini-ruby (magenta) and were stained for RGS14 (green) and 5HT3aR (green), respectively. Sections have been counterstained with DAPI (blue) to visualize cell nuclei. Yellow arrowheads mark sites imaged to obtain data presented in Fig. 9
Fig. 10We used systematic random sampling to estimate the total number of contacts between VM axon terminals in the uppermost 40 μm of prelimbic cortex and dendrites of pyramidal neurons marked with MAP2, dendrites of CS neurons marked with RGS14 and dendrites of 5HT3aR-positive inhibitory interneurons in layer I. The estimated number of contacts for each of the seven animals are indicated by black dots. The mean and standard error of the mean for the estimated total amount of contacts are indicated in red
Estimated total amount of contacts for all seven animals between ventromedial thalamic axon terminals in uppermost prelimbic cortical layer I and dendrites of pyramidal neurons marked with MAP2, dendrites of CS neurons marked with RGS14 and dendrites of 5HT3aR-positive inhibitory interneurons in layer I
| Cortical pyramidal neurons (MAP2) | CS neurons (RGS14) | Layer I inhibitory interneurons (5HT3aR) | |
|---|---|---|---|
| Animal 1 | 10,391 | 9108 | 8284 |
| Animal 2 | 12,896 | 12,880 | 10,878 |
| Animal 3 | 12,530 | 11,175 | 10,980 |
| Animal 4 | 14,376 | 10,225 | 9120 |
| Animal 5 | 29,393 | 23,566 | 18,251 |
| Animal 6 | 6650 | 6270 | 5413 |
| Animal 7 | 30,477 | 20,757 | 18,624 |
| Mean | 16,673 | 13,426 | 11,650 |
The mean is given in the bottom row